5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

Nina Wagner-Johnston, Jeff A. Sloan, Heshan Liu, Ann E. Kearns, Stephanie L. Hines, Suneetha Puttabasavaiah, Shaker R. Dakhil, Jacqueline M. Lafky, Edith A. Perez, Charles L. Loprinzi

Research output: Contribution to journalArticle


BACKGROUND Postmenopausal women with breast cancer receiving aromatase inhibitors are at an increased risk of bone loss. The current study was undertaken to determine whether upfront versus delayed treatment with zoledronic acid (ZA) impacted bone loss. This report described the 5-year follow-up results. METHODS A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months. In the patients on the delayed treatment arm, ZA was initiated for a postbaseline bone mineral density T-score of

Original languageEnglish (US)
Pages (from-to)2537-2543
Number of pages7
Issue number15
Publication statusPublished - Aug 1 2015
Externally publishedYes



  • bone loss
  • breast cancer
  • letrozole
  • postmenopausal
  • tamoxifen
  • zoledronic acid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this